Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO plus IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227

被引：1

作者：

Peters, S. ^{[1
]}

Penrod, J. ^{[2
]}

Li, J. ^{[2
]}

Lubinga, S. ^{[2
]}

Gupta, R. ^{[2
]}

Bushong, J. ^{[2
]}

Rizzo, J. ^{[2
]}

Ramalingam, S. ^{[3
]}

机构：

[1] Lausanne Univ Hosp, Dept Oncol UNIL CHUV, Lausanne, Switzerland

[2] Bristol Myers Squibb, Princeton, NJ USA

[3] Emory, Winship Canc Inst, Atlanta, GA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.02.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10P

引用

页码：S32 / S33

页数：2

共 50 条

[21] Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Reck, Martin
Ciuleanu, Tudor-Eliade
Dols, Manuel Cobo
Schenker, Michael
Zurawski, Bogdan
Menezes, Juliana
Richardet, Eduardo
Bennouna, Jaafar
Felip, Enriqueta
Juan-Vidal, Oscar
Alexandru, Aurella
Sakai, Hiroshi
Scherpereel, Arnaud
Lu, Shun
John, Thomas
Carbone, David Paul
Meadows-Shropshire, Stephanie
Yan, Jinchun
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[22] Six-year survival and HRQoL outcomes with 1L nivolumab (N) plus ipilimumab (I) vs chemotherapy (C) in patients with metastatic NSCLC (mNSCLC) from CheckMate227
Ramalingam, Suresh S.
Ciuleanu, Tudor-Eliade
Bernabe Caro, Reyes
Nishio, Makoto
Mizutani, Hideaki
Lee, Jong-Seok
Audigier-Valette, Clarisse
Sangha, Randeep
Urban, Laszlo
Burgers, Jacobus A.
Pluzanski, Adam
Lee, Ki Hyeong
Zurawski, Bogdan
Schenker, Michael
Peters, Solange
Paz-Ares, Luis
Borghaei, Hossein
O'byrne, Kenneth
Brahmer, Julie R.
Gupta, Ravi G.
Bushong, Judith
Li, Li
Yuan, Yong
Blum, Steven
Reck, Martin
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 129 - 130
[23] Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer
Feldman, Hope
Sepesi, Boris
Leung, Cheuk H.
Lin, Heather
Weissferdt, Annikka
Pataer, Apar
William Jr, William N.
Walsh, Garrett L.
Rice, David C.
Roth, Jack A.
Mehran, Reza J.
Hofstetter, Wayne L.
Antonoff, Mara B.
Rajaram, Ravi
Gibbons, Don L.
Lee, J. Jack
Heymach, John V.
Vaporciyan, Ara A.
Swisher, Stephen G.
Cascone, Tina
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (04):
[24] Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Brahmer, Julie R.
Lee, Jong-Seok
Ciuleanu, Tudor-Eliade
Bernabe Caro, Reyes
Nishio, Makoto
Urban, Laszlo
Audigier-Valette, Clarisse
Lupinacci, Lorena
Sangha, Randeep
Pluzanski, Adam
Burgers, Jacobus
Mahave, Mauricio
Ahmed, Samreen
Schoenfeld, Adam J.
Paz-Ares, Luis G.
Reck, Martin
Borghaei, Hossein
O'Byrne, Kenneth J.
Gupta, Ravi G.
Bushong, Judith
Li, Li
Blum, Steven I.
Eccles, Laura J.
Ramalingam, Suresh S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1200 - +
[25] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
Paz-Ares, Luis G.
Ciuleanu, Tudor-Eliade
Cobo-Dols, Manuel
Bennouna, Jaafar
Cheng, Ying
Mizutani, Hideaki
Lingua, Alejo
Reyes, Felipe
Reinmuth, Niels
De Menezes, Juliana Janoski
Jassem, Jacek
Protsenko, Svetlana
Feeney, Kynan
Jimenez, Emmanuel De La Mora
Lu, Shun
John, Tom
Carbone, David Paul
Zhang, Xiaoqing
Hu, Nan
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[26] Nivolumab (N) plus Low-Dose Ipilimumab (I) vs Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment (tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Checkmate 227 Part 1 Final Analysis
Reck, Martin
Peters, Solange
Ramalingam, Suresh
Paz-Ares, Luis
Bernabe Caro, Reyes
Zurawski, Bogdan
Kim, Sang-We
Alexandru, Aurelia
Lupinacci, Lorena
de la Mora Jitnenez, Emmanuel
Sakai, Hiroshi
Albert, Istvan
Vergnenegre, Alain
Borghaei, Hossein
Brahmer, Julie R.
O'byrne, Kenneth
Geese, William J.
Bhagavatheeswaran, Prabhu
Nattan, Faith E.
Hellmann, Matthew D.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 233 - 234
[27] Nivolumab plus ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
Ramalingam, Suresh S.
Ciuleanu, Tudor Eliade
Pluzanski, Adam
Lee, Jong-Seok
Schenker, Michael
Caro, Reyes Bernabe
Lee, Ki Hyeong
Zurawski, Bogdan
Audigier-Valette, Clarisse
Provencio, Mariano
Linardou, Helena
Kim, Sang-We
Borghaei, Hossein
Hellmann, Matthew David
O'Byrne, Kenneth John
Paz-Ares, Luis G.
Reck, Martin
Nathan, Faith Ellen
Brahmer, Julie R.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[28] Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
Reck, M.
De, T.
Paz-Ares, L.
Yuan, Y.
Chaudhary, A.
Lee, A.
Varol, N.
Penrod, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1024 - S1024
[29] Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer
Feldman, Hope
Bott, Matthew
Mehran, Reza J.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (04): : 1454 - 1455
[30] Six-year Survival and HRQoL Outcomes with 1L Nivolumab plus Ipilimumab in Patients with Metastatic NSCLC from CheckMate227
Ramalingam, S. S.
Ciuleanu, T. -E.
Bernabe Caro, R.
Nishio, M.
Mizutani, H.
Lee, J. -S.
Audigier-Valette, C.
Sangha, R.
Urban, L.
Burgers, J. A.
Pluzanski, A.
Lee, K. H.
Zurawski, B.
Schenker, M.
Peters, S.
Paz-Ares, L. G.
Borghaei, H.
O'Byrne, K. J.
Brahmer, J. R.
Gupta, R. G.
Bushong, J.
Li, L.
Yuan, Y.
Blum, S. I.
Reck, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S76 - S77

← 1 2 3 4 5 →